Brain type natriuretic peptide (BNP)—A marker of new millennium in diagnosis of congestive heart failure

Raizada, Arun; Bhandari, Suman; Khan, Muzaiyan Ahmed; Singh, Harsh Vardhan; Thomas, Sherin Sarah; Sarabhai, V.; Singh, Neelima; Trehan, Naresh

doi:10.1007/bf02912873

Cited by 16 publications

(16 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BNP was originally named brain natriuretic peptide, and it was first detected in porcine brain 27,28. BNP levels have been found elevated in patients with various clinical conditions such as heart failure, MI, left ventricular hypertrophy, cardiac inflammation, primary pulmonary hypertension, renal failure, ascetic cirrhosis and is associated with advanced age 29. The levels correlate with severity of symptoms and with prognosis, and so it helps to detect the presence of heart failure, determine its severity, and estimate prognosis.…”

Section: Clinically Relevant Cardiac Markersmentioning

confidence: 99%

Novel Cardiac-Specific Biomarkers and the Cardiovascular Continuum

2012

View full text Add to dashboard Cite

The concept of the cardiovascular continuum, introduced during the early 1990s, created a holistic view of the chain of events connecting cardiovascular-related risk factors with the progressive development of pathological-related tissue remodelling and ultimately, heart failure and death. Understanding of the tissue-specific changes, and new technologies developed over the last 25–30 years, enabled tissue remodelling events to be monitored in vivo and cardiovascular disease to be diagnosed more reliably than before. The tangible product of this evolution was the introduction of a number of biochemical markers such as troponin I and T, which are now commonly used in clinics to measure myocardial damage. However, biomarkers that can detect specific earlier stages of the cardiovascular continuum have yet to be generated and utilised. The majority of the existing markers are useful only in the end stages of the disease where few successful intervention options exist. Since a large number of patients experience a transient underlying developing pathology long before the signs or symptoms of cardiovascular disease become apparent, the requirement for new markers that can describe the early tissue-specific, matrix remodelling process which ultimately leads to disease is evident. This review highlights the importance of relating cardiac biochemical markers with specific time points along the cardiovascular continuum, especially during the early transient phase of pathology progression where none of the existing markers aid diagnosis.

show abstract

Section: Clinically Relevant Cardiac Markersmentioning

confidence: 99%

Novel Cardiac-Specific Biomarkers and the Cardiovascular Continuum

2012

View full text Add to dashboard Cite

show abstract

“…BNP levels often increase in various cardiac and noncardiac conditions including MI, heart failure, pulmonary hypertension, renal failure, and cirrhosis, and may be used to gauge symptom severity and prognosis (45). Amino terminal pro-brain natriuretic peptide (NT-proBNP) has been cleared by the FDA for assessing the prognosis of patients with congestive heart failure and ACS (45). The BNP assay is also cleared by the FDA for risk stratification in ACS (46).…”

Section: Assays For Detection Of Acute Coronary Syndromementioning

confidence: 99%

Novel Risk Stratification Assays for Acute Coronary Syndrome

Ahmed

Hazen

2017

Curr Cardiol Rep

View full text Add to dashboard Cite

Since identification of aspartate aminotransferase as the first cardiac biomarker in the 1950s, there have been a number of new markers used for myocardial damage detection over the decades. There have also been several generations of troponin assays, each with progressively increasing sensitivity for troponin detection. As of this writing, a fifth “next” generation troponin assay has now been cleared by the US Food and Drug Administration for clinical use in the United States for subjects presenting with suspected acute coronary syndromes. In this review we discuss novel assays available for the risk assessment of subjects presenting with chest pain, including both the “next generation” cardiac troponin assays as well as other novel biomarkers. We review the biological mechanisms for these markers, and explore the positive and negative predictive value of the assays in clinical studies, where reported. We also discuss the potential use of these new markers within the context of future clinical care in the modern era of higher sensitivity troponin testing. Finally, we discuss advances in new platforms (eg. mass spectrometry) that historically have not been considered for rapid in vitro diagnostic capabilities, but that are taking a larger role in clinical diagnostics, and whose prognostic value and power promise to usher in new markers with potential for future clinical utility in acute coronary syndrome.

show abstract

“…In the human population, the most common presentation of CVD is congestive heart failure, which is also the leading cause of morbidity, mortality, and hospitalization. This illness is primarily a vascular disease often related to diet and exercise [ 6 ]. In contrast, in great apes the most common form of CVD is fibrosing cardiomyopathy of as yet unknown etiology.…”

Section: Introductionmentioning

confidence: 99%

Diagnosing cardiovascular disease in western lowland gorillas (Gorilla gorilla gorilla) with brain natriuretic peptide

et al. 2019

View full text Add to dashboard Cite

Cardiovascular disease is a leading cause of death in zoo-housed great apes, accounting for 41% of adult gorilla death in North American zoological institutions. Obtaining a timely and accurate diagnosis of cardiovascular disease in gorillas is challenging, relying on echocardiography which generally requires anesthetic medications that may confound findings and can cause severe side effects in cardiovascularly compromised animals. The measurement of brain natriuretic peptide (BNP) has emerged as a modality of interest in the diagnosis, prognosis and treatment of human patients with heart failure. This study evaluated records for 116 zoo-housed gorillas to determine relationships of BNP with cardiovascular disease. Elevations of BNP levels correlated with the presence of visible echocardiographic abnormalities, as well as reported clinical signs in affected gorillas. Levels of BNP greater 150 pb/mL should alert the clinician to the presence of myocardial strain and volume overload, warranting medical evaluation and intervention.

show abstract

Brain type natriuretic peptide (BNP)—A marker of new millennium in diagnosis of congestive heart failure

Cited by 16 publications

References 32 publications

Novel Cardiac-Specific Biomarkers and the Cardiovascular Continuum

Novel Cardiac-Specific Biomarkers and the Cardiovascular Continuum

Novel Risk Stratification Assays for Acute Coronary Syndrome

Diagnosing cardiovascular disease in western lowland gorillas (Gorilla gorilla gorilla) with brain natriuretic peptide

Contact Info

Product

Resources

About